AOL
AbbVie's tight grip on Humira market raises concerns about biosimilars
Humira, which lists for almost $7,000 a month, is the first top-selling drug to compete with a slew of biosimilars, which are close but not exact copies of branded biologic medicines. But after ...
1 hour ago